Daiichi Sankyo Co Ltd 2019 IR
The report outlines Daiichi Sankyo's strategic transition toward becoming a global pharma innovator with a competitive advantage in oncology, highlighted by its landmark collaboration with AstraZeneca for the development and commercialization of DS-8201. During fiscal year 2018, the company expanded the global market share of its mainstay anticoagulant LIXIANA and successfully launched new products like Tarlige and Minnebro in Japan. On the sustainability front, Daiichi Sankyo became the first Japanese pharmaceutical company to support the TCFD recommendations and had its greenhouse gas reduction targets approved by the Science Based Targets initiative. Financially, the company reported a revenue of 929.7 billion yen and achieved a 12.7% reduction in CO2 emissions compared to the 2015 baseline.
Company: Daiichi Sankyo Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2019
Type: IR
Pages: 59
Back to company
Daiichi Sankyo Co Ltd
Value Report
The report outlines Daiichi Sankyo's strategic transition toward becoming a global pharma innovator with a competitive advantage in oncology, highlighted by its landmark collaboration with AstraZeneca for the development and commercialization of DS-8201. During fiscal year 2018, the company expanded the global market share of its mainstay anticoagulant LIXIANA and successfully launched new products like Tarlige and Minnebro in Japan. On the sustainability front, Daiichi Sankyo became the first Japanese pharmaceutical company to support the TCFD recommendations and had its greenhouse gas reduction targets approved by the Science Based Targets initiative. Financially, the company reported a revenue of 929.7 billion yen and achieved a 12.7% reduction in CO2 emissions compared to the 2015 baseline.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 1, 2018 - Mar 31, 2019
Fiscal Year
2018
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Women in Management
Employees